Market Place
Sourcing Support
All News #Library
Biotech
Palleon Pharma Showcases HLX79/E-602 For Autoimmune Disease
22 Oct 2025 //
BUSINESSWIRE
1st Patient Dosed in Palleon`s Ph 2 Trial for Glomerulonephritis
07 Aug 2025 //
BUSINESSWIRE
Palleon Pharmaceuticals: NMPA IND Clearance for E-602 Phase 2 Trial
02 Apr 2025 //
BUSINESSWIRE
Palleon & Henlius Partner to Advance Glycan for Autoimmune Diseases
19 Dec 2024 //
BUSINESSWIRE
Palleon Pharma GLIMMER-01 E-602 + Cemiplimab Data at SITC
08 Nov 2024 //
BUSINESSWIRE
Palleon Pharma Recognized as a Fierce Biotech “Fierce 15” Company for 2023
28 Aug 2023 //
BUSINESSWIRE
Palleon Pharma First Patient Dosed with E-602 in Combination with Cemiplimab
22 Jun 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.